COMPASS Pathways Framtida tillväxt
Future kriterier kontrolleras 5/6
COMPASS Pathways förväntas öka intäkter och intäkter med 65.9% respektive 65.1% per år. EPS förväntas tillväxt med 64.5% per år. Avkastningen på eget kapital förväntas bli -110.1% om 3 år.
Viktig information
65.9%
Tillväxttakt i vinsten
64.48%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 27.2% |
| Intäkternas tillväxttakt | 65.1% |
| Framtida avkastning på eget kapital | -110.07% |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 05 Aug 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Seeking Alpha • Jul 28
Compass Pathways: The Psilocybin Biotech Leader With Strong Momentum
Summary CMPS leads regulated psilocybin with two successful Phase 3 trials and a rolling FDA submission, giving COMP360 a valuable head start in treatment-resistant depression. The core case rests on vast unmet need in depression, while encouraging PTSD data and other possible uses provide meaningful long-term upside beyond the first indication. Lilly’s move for Atai validates the field and raises the competitive bar, but CMPS retains its clinical lead and cash runway; a 2% pro-forma position keeps risk proportionate. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jul 23
CMPS: Phase 3 Durability And Favorable FDA Stance Will Drive Upside
Analysts have raised the fair value estimate for Compass Pathways stock to $17.00 from $8.00, citing stronger confidence in COMP360's durable efficacy profile, supportive recent Phase 3 data, and a regulatory backdrop that they view as increasingly receptive to psychedelic treatments. Analyst Commentary Recent Street research on Compass Pathways highlights a mix of enthusiasm around COMP360's Phase 3 data and a more cautious undercurrent that focuses on execution, valuation, and regulatory timing.
Uppdatering av berättelse • Jul 08
CMPS: Phase 3 Durability Data Will Underpin Potential 2027 Launch Upside
The analyst price target for Compass Pathways has been raised to $24.47 from $21.92. Analysts point to supportive 26-week COMP360 durability data, a consistent safety profile, and a clearer path toward a potential 2027 approval and commercial launch as key reasons for the updated view.
Ny berättelse • Apr 02
Phase III Progress And PTSD Expansion Will Reshape Long Term Psychedelic Mental Health Treatment
Catalysts About COMPASS Pathways COMPASS Pathways is a mental health company developing COMP360 psilocybin treatment for conditions such as treatment resistant depression and PTSD. What are the underlying business or industry changes driving this perspective?Ny berättelse • Mar 19
Phase III Completion And PTSD Expansion Will Support A Durable Mental Health Franchise
Catalysts About COMPASS Pathways COMPASS Pathways is a mental health company developing COMP360 psilocybin treatment for conditions such as treatment resistant depression and PTSD. What are the underlying business or industry changes driving this perspective?Ny berättelse • Mar 04
Phase III Trial Dependence Will Dominate Near Term While Long Term Potential Remains
Catalysts About COMPASS Pathways COMPASS Pathways is a mental health company developing COMP360, a psilocybin-based treatment for conditions such as treatment resistant depression and PTSD. What are the underlying business or industry changes driving this perspective?Analysartikel • Dec 08
Is COMPASS Pathways (NASDAQ:CMPS) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Aug 07
Is COMPASS Pathways (NASDAQ:CMPS) Using Debt Sensibly?
NasdaqGS:CMPS 1 Year Share Price vs Fair Value Explore COMPASS Pathways's Fair Values from the Community and select...Seeking Alpha • Feb 28
Compass Pathways: Betting On The Future Of Psilocybin Therapy
Summary Compass Pathways is positioned to leverage regulatory tailwinds and compelling clinical data, despite broader skepticism and high cash burn in the psychedelic biotech sector. The company has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before needing additional capital. COMP360 shows promise in treating treatment-resistant depression and PTSD, with significant clinical trial results and potential long-term economic benefits. Regulatory hurdles and scientific doubts remain, but if Compass achieves FDA approval, its current market valuation could be deeply discounted relative to its long-term potential. Read the full article on Seeking AlphaAnalysartikel • Jan 04
Does COMPASS Pathways (NASDAQ:CMPS) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Nov 01
Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity
Summary Compass Pathways plc obtained positive results from phase 2b study using COMP360 for treatment resistant depression patients; Primary endpoint met with statistically significant p-value of p<0.001. Top-line results from the phase 3 COMP005 study, using COMP360 for treatment-resistant depression patients, expected in Q2 of 2025. The global treatment-resistant depression treatment market size is projected to grow to $4 billion by 2033. Other indications being explored using COMP360 as a synthetic psilocybin are anorexia nervosa and post-traumatic stress disorder. Read the full article on Seeking AlphaSeeking Alpha • Aug 19
Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision
Summary The psychedelics sector has suffered a big blow, with the US FDA knocking back a New Drug Application for MDMA-assisted therapy. The potential for a negative FDA decision had been well-flagged by an advisory committee report in June, so the market may have already priced in the downside. Arguments that the negative FDA decision on MDMA may actually be good news for Compass Pathways plc and peers are not persuasive. The FDA decision is not the end of the road for the psychedelics sector, but Compass Pathways and peers face serious challenges regarding regulatory approval, access to capital and commercialization. The group took action to strengthen its balance sheet in 2023, but my cash burn analysis indicates that further capital injections will be needed before the end of 2025. Read the full article on Seeking AlphaSeeking Alpha • Jul 08
Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies
Summary COMPASS Pathways' lead drug, COMP360, is a synthetic psilocybin in Phase 3 trials for TRD and Phase 2 for PTSD and AN. The company addresses unmet mental health needs through psychedelic therapies. COMP360 showed promising results in Phase 2 trials for PTSD, with significant improvements in depression symptoms. Industry-wide regulatory uncertainties persist, highlighted by the FDA's recent decision against MDMA for PTSD. I believe CMPS is undervalued. Its substantial aggregate TAM and strategic collaborations bode well for potential FDA approval and commercialization. Read the full article on Seeking AlphaSeeking Alpha • May 23
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
Summary Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements. Analyst Alex Carchidi discusses Compass, Cybin, Atai, and MindMed seeing improvements in their balance sheets and clinical trial data. Read the full article on Seeking AlphaSeeking Alpha • Apr 25
COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
Summary The US FDA is due to make a decision regarding MDMA-assisted therapy in August 2024 – this will be a critical event for the future of COMPASS Pathways. COMPASS Pathways’ share price has exhibited extreme volatility over the last year, highlighting the speculative nature of investing in the psychedelics sector. COMPASS Pathways has experienced delays with its COMP 005 clinical trial, but is confident that its COMP360 New Drug Application timeline remains unchanged. The departure of the company’s co-founders came as a surprise, and follows on from the sudden exit of the group’s CFO in late 2023. Read the full article on Seeking AlphaSeeking Alpha • Feb 08
Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
Summary Compass Pathways plc, a biotech company based in London, is developing a psilocybin-based therapy for CNS disorders. The company's shares declined by over 80% in 2022 due to safety concerns and regulatory hurdles. Psilocybin is classified as a Schedule I substance in the U.S., posing challenges for commercial marketing in the country. Compass' COMP-360 therapy involves sessions with therapists and digital support, and has met efficacy endpoints in a Phase 2 study. There are multiple reasons to doubt the therapy can be approved, and Compass has a high cash burn, but Phase 3 data due this year may support an approval push, if positive. An interesting contrarian play, for those with a higher appetite for risk. Read the full article on Seeking AlphaAnalysartikel • Dec 06
Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Oct 19
Booker again pushes for easier access to psychedelics for terminally ill patients
Sen. Cory Booker (D-N.J.) is again pushing for easier access to psychedelic drugs, including psilocybin, the active psychedelic compound in "magic mushrooms," and MDMA, for terminally ill patients. In July, Booker and Sen. Rand Paul (R-Ky.) introduced legislation to clarify that the Right to Try Act allows for access to some psychedelics and cannabis. Companion legislation was also filed in the House. In a video posted to Twitter, Booker said that psilocybin and MDMA particularly "are showing incredible results for helping people with PTSD, with trauma, even with anxiety and depression." Several companies are examining psychedelics for mental health disorders, including COMPASS Pathways (NASDAQ:CMPS), Cybin (NYSE:CYBN), atai Life Sciences (NASDAQ:ATAI), and MindMed (NASDAQ:MNMD). Check out why Seeking Alpha contributor Stephen Tobin is bullish on atai Life Sciences (ATAI).Analysartikel • Aug 13
Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 231 | -69 | -73 | -106 | 11 |
| 12/31/2027 | 66 | -213 | -198 | -158 | 12 |
| 12/31/2026 | N/A | -103 | -199 | -211 | 14 |
| 6/30/2026 | N/A | -394 | -161 | -161 | N/A |
| 3/31/2026 | N/A | -192 | -160 | -160 | N/A |
| 12/31/2025 | N/A | -288 | -157 | -157 | N/A |
| 9/30/2025 | N/A | -237 | -161 | -161 | N/A |
| 6/30/2025 | N/A | -138 | -148 | -148 | N/A |
| 3/31/2025 | N/A | -138 | -144 | -144 | N/A |
| 12/31/2024 | N/A | -155 | -119 | -119 | N/A |
| 9/30/2024 | N/A | -144 | -105 | -105 | N/A |
| 6/30/2024 | N/A | -139 | -100 | -100 | N/A |
| 3/31/2024 | N/A | -129 | -91 | -90 | N/A |
| 12/31/2023 | N/A | -118 | -97 | -97 | N/A |
| 9/30/2023 | N/A | -117 | -115 | -115 | N/A |
| 6/30/2023 | N/A | -102 | -117 | -117 | N/A |
| 3/31/2023 | N/A | -95 | -111 | -110 | N/A |
| 12/31/2022 | N/A | -92 | -106 | -105 | N/A |
| 9/30/2022 | N/A | -86 | -83 | -83 | N/A |
| 6/30/2022 | N/A | -84 | -78 | -77 | N/A |
| 3/31/2022 | N/A | -80 | -77 | -77 | N/A |
| 12/31/2021 | N/A | -72 | -68 | -68 | N/A |
| 9/30/2021 | N/A | -65 | -62 | -62 | N/A |
| 6/30/2021 | N/A | -66 | -62 | -62 | N/A |
| 3/31/2021 | N/A | -64 | -51 | -51 | N/A |
| 12/31/2020 | N/A | -60 | -42 | -41 | N/A |
| 9/30/2020 | N/A | -49 | -31 | -31 | N/A |
| 6/30/2020 | N/A | -38 | -22 | -22 | N/A |
| 3/31/2020 | N/A | -25 | N/A | -19 | N/A |
| 12/31/2019 | N/A | -20 | N/A | -18 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: CMPS förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 3.5% ).
Resultat vs marknad: CMPS förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.
Höga tillväxtresultat: CMPS förväntas bli lönsam under de kommande 3 åren.
Intäkt vs marknad: CMPS s intäkter ( 65.1% per år) förväntas växa snabbare än US marknaden ( 12.8% per år).
Hög tillväxtintäkter: CMPS s intäkter ( 65.1% per år) förutspås växa snabbare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: CMPS förväntas bli olönsam om 3 år.
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/05 08:41 |
| Aktiekurs vid dagens slut | 2026/08/05 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
COMPASS Pathways plc bevakas av 22 analytiker. 14 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |